Intelligence · Clinical Pipeline
Nanjing Legend Biotech Pipeline
All ClinicalTrials.gov programs at Nanjing Legend Biotech — phase, modality, and trial IDs.
- Programs
- 31
Quick answer
Nanjing Legend Biotech has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
CAR-T Re-treatment
Nanjing Legend Biotech Co.
Multiple Myeloma
1 trial -
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
Nanjing Legend Biotech Co.
Relapsed/Refractory B-cell Malignancies
1 trial -
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Nanjing Legend Biotech Co.
Lymphoma, B-Cell
1 trial -
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
Nanjing Legend Biotech Co.
Refractory B Acute Lymphoblastic Leukemia
1 trial -
Efficacy of LCAR-T2C CAR-T cells
Nanjing Legend Biotech Co.
T Cell Lymphoma
1 trial -
Efficacy of LCAR-T2C CAR-T cells
Nanjing Legend Biotech Co.
CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)
1 trial -
LB1901
Nanjing Legend Biotech Co.
T-Cell Lymphoma
1 trial -
LB1908
Nanjing Legend Biotech Co.
Gastric Cancer
1 trial -
LB2102
Nanjing Legend Biotech Co.
Small Cell Lung Cancer Extensive Stage
1 trial -
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Relapsed/Refractory Autoimmune Diseases
1 trial -
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Systemic Lupus Erythematosus (SLE)
1 trial -
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Multiple Sclerosis (MS)
1 trial -
LCAR-AIO cells product
Nanjing Legend Biotech Co.
B-cell Lymphoma Recurrent
1 trial -
LCAR-AMDR Cells Product
Nanjing Legend Biotech Co.
Acute Myeloid Leukemia
1 trial -
LCAR-B4822M CAR-T Cell Immunotherapy
Nanjing Legend Biotech Co.
Refractory or Relapsed Multiple Myeloma
1 trial -
LCAR-BCDR cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LCAR-BCX cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LCAR-C182A cells
Nanjing Legend Biotech Co.
Gastric Cancer
1 trial -
LCAR-C18S cells
Nanjing Legend Biotech Co.
Solid Tumors, Adult
1 trial -
LCAR-G08 cells
Nanjing Legend Biotech Co.
Advanced Gastrointestinal Tumors
1 trial -
LCAR-HL30 cells
Nanjing Legend Biotech Co.
Hodgkin's Lymphoma
1 trial -
LCAR-M23 cells
Nanjing Legend Biotech Co.
Epithelial Ovarian Cancer
1 trial -
LUCAR-20S CAR-T cells
Nanjing Legend Biotech Co.
Diffuse Large B Cell Lymphoma
1 trial -
LUCAR-20SP cells
Nanjing Legend Biotech Co.
Relapsed B-cell Non-Hodgkin Lymphoma
1 trial -
LUCAR-B68 cells product
Nanjing Legend Biotech Co.
Relapsed/Refractory Multiple Myeloma
1 trial -
LUCAR-DKS1 NK cells
Nanjing Legend Biotech Co.
Relapsed/Refractory Autoimmune Diseases
1 trial -
LUCAR-G39D cells product
Nanjing Legend Biotech Co.
B-Cell Non-Hodgkin Lymphoma-Recurrent
1 trial -
LUCAR-G79 T cells
Nanjing Legend Biotech Co.
Relapsed/Refractory Autoimmune Diseases
1 trial -
LUCAR-G79D T cells
Nanjing Legend Biotech Co.
Systemic Lupus Erythematosus (SLE)
1 trial -
LVIVO-TaVec400 product
Nanjing Legend Biotech Co.
Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)
1 trial -
anti-CD123 CAR-T treatment
Nanjing Legend Biotech Co.
Acute Leukemia
1 trial
Frequently asked questions
How many pipeline programs does Nanjing Legend Biotech have?
31 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs